Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing

Abstract

We report an approximately 80% reduction in angioedema attacks with lanadelumab, a mAb targeting plasma kallikrein, in a case of hereditary angioedema with normal C1 inhibitor levels. This finding supports a central pathophysiologic role for kallikrein in hereditary angioedema with normal C1 levels and supports the need for prospective studies of lanadelumab use with this condition.

Keywords

• Hereditary angioedema
• hereditary angioedema with normal C1 inhibitor
• lanadelumab
• icatibant
• immune deficiency